SNDX Syndax Pharmaceuticals Inc
Q3 2025 10-Q
Syndax Pharmaceuticals Inc (SNDX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New regulatory risk: ongoing U.S. government shutdown since Oct 1, 2025 may delay FDA's review of regulatory submissions, material adverse effect possible
- • Updated competition risk: FDA approved Imbruvica, Rezurock, Jakafi for cGVHD, challenging Niktimvo’s market adoption and limiting commercial scope
Quarterly Financial SummaryXBRL
Revenue
$46M
▲ +267.0% YoY▲ +21.6% QoQ
Net Income
-$61M
▲ +27.8% YoY▲ +15.5% QoQ
Operating Margin
-125.2%
▲ +59143bp YoY▲ +5872bp QoQ
Net Margin
-132.4%
▲ +54065bp YoY▲ +5816bp QoQ
ROE
-52.6%
Total Assets
$552M
EPS (Diluted)
$-0.69
▲ +29.6% YoY▲ +17.9% QoQ
Operating Cash Flow
-$71M
▼ -13.2% YoY▲ +19.7% QoQ
Source: XBRL data from Syndax Pharmaceuticals Inc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Syndax Pharmaceuticals Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.